377 related articles for article (PubMed ID: 25564602)
1. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
2. The drug that could have been.
Schultz S
US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
[No Abstract] [Full Text] [Related]
3. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
[No Abstract] [Full Text] [Related]
4. Cancer drug prices and the free-market forces.
Kantarjian H; Zwelling L
Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
[No Abstract] [Full Text] [Related]
5. Market spiral pricing of cancer drugs.
Light DW; Kantarjian H
Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
[No Abstract] [Full Text] [Related]
6. Cost of Cancer Drugs: Something Has To Give.
Bender E
Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
[TBL] [Abstract][Full Text] [Related]
7. Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy.
Eaglstein WH
JAMA Dermatol; 2016 Feb; 152(2):139-40. PubMed ID: 26606648
[No Abstract] [Full Text] [Related]
8. India spurns cancer patents.
Hayden EC
Nature; 2013 Aug; 500(7462):266. PubMed ID: 23955214
[No Abstract] [Full Text] [Related]
9. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
Bach PB; Giralt SA; Saltz LB
JAMA; 2017 Nov; 318(19):1861-1862. PubMed ID: 28975266
[No Abstract] [Full Text] [Related]
10. Novel schemes skirt NICE barrier.
Elvidge S
Nat Biotechnol; 2011 Aug; 29(8):677. PubMed ID: 21822231
[No Abstract] [Full Text] [Related]
11. Beyond fast track for drug approvals.
Roberts TG; Chabner BA
N Engl J Med; 2004 Jul; 351(5):501-5. PubMed ID: 15282359
[No Abstract] [Full Text] [Related]
12. Market watch: Upcoming catalysts in Q1 2015.
Uribe A
Nat Rev Drug Discov; 2015 Jan; 14(1):9. PubMed ID: 25503330
[No Abstract] [Full Text] [Related]
13. Pushback on Zaltrap's price highlights sensitive end-of-life issue.
Dalzell MD
Manag Care; 2012 Dec; 21(12):40-1. PubMed ID: 23304735
[No Abstract] [Full Text] [Related]
14. Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.
Davies BJ; Hwang TJ; Kesselheim AS
N Engl J Med; 2017 Apr; 376(15):1401-1403. PubMed ID: 28402764
[No Abstract] [Full Text] [Related]
15. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
16. US hospitals object to changes in Genentech drug distribution.
Furlow B
Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290
[No Abstract] [Full Text] [Related]
17. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
18. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
19. 3 New Biologics To Be Worth $14B in Sales by 2019.
Adams KT
Manag Care; 2015 May; 24(5):36-7. PubMed ID: 26117964
[No Abstract] [Full Text] [Related]
20. Tackling Cost: A Prescription for Spending Wisely.
Tempero M
J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
[No Abstract] [Full Text] [Related]
[Next] [New Search]
